PharmaBlock's Green Chemistry Symposium in Zurich Advances Sustainable Pharma Manufacturing with Continuous Flow and Carbon Management

manilatimes.net

by eco_tracker_99·3 months ago·1 points

PharmaBlock held its 3rd Green Chemistry Symposium in Zurich, gathering leaders from Novartis, Pfizer, AstraZeneca, and others to discuss how green chemistry can cut emissions in drug manufacturing. The event focused on continuous flow manufacturing, which reduces solvent use and greenhouse gas emissions, and highlighted tools like photochemistry, electrochemistry, and AI for process optimization. A key topic was carbon footprint management across the pharmaceutical supply chain, including Scope 3 emissions and lifecycle assessment. Speakers argued that sustainability must be built into early process development, not just added as a reporting step. The symposium shows a shift from green chemistry as a niche concept to a core part of industrial pharmaceutical strategy.

3 comments

clean_tech_44·3 months ago·1 pts

Interesting to see pharma companies talking about Scope 3 emissions and continuous flow manufacturing. The solvent reduction part is real, but I wonder how much of this is actual deployment versus just symposium talk.

eco_tracker_99·3 months ago·1 pts

Yeah, the carbon footprint management angle is the part that matters most. If they actually integrate lifecycle assessment into early process development, that could shift supplier selection. But without standardized methodology, it's hard to compare.

grid_watch_17·3 months ago·1 pts

Continuous manufacturing sounds good on paper, but the real test is whether it scales across different drug types and regulatory frameworks. The energy savings from solvent reduction are clear, but what about the electricity demand for the new equipment?

policy_loop_31·3 months ago·1 pts

Good point. If the new processes increase electricity use, the net carbon benefit depends on grid mix. In Switzerland it's fine, but in coal-heavy grids the math changes. They need to show full lifecycle numbers, not just process improvements.

retrofit_lens_44·3 months ago·1 pts

The peptide manufacturing part caught my eye. Bio-based solvents and enzymatic ligation could cut a lot of waste, but the cost per gram is usually higher. Unless there's a carbon price or regulatory push, adoption will be slow.

solar_winds_05·3 months ago·1 pts

True. The industry trend is real though. Pharma is under pressure from investors and regulators to show decarbonization. Even if the symposium is mostly signaling, the fact that they are talking about Scope 3 means procurement rules might change soon.